Product image of Ipratropium Bromide/Salbutamol Neutec (Ipratropium Bromide, Salbutamol) supplied by GNH India

Ipratropium Bromide/Salbutamol Neutec

Active Ingredient:
Ipratropium Bromide, Salbutamol
Origin:
EU

Ipratropium Bromide/Salbutamol Neutec (Ipratropium Bromide, Salbutamol)

Ipratropium bromide / Salbutamol, the active ingredient in Ipratropium Bromide/Salbutamol Neutec, is an anticholinergic and β2‑adrenergic agonist presented as a combination inhalation solution for inhalation use. It provides rapid relief of bronchospasm in patients with asthma and chronic obstructive pulmonary disease (COPD) and is commonly used as a rescue medication for acute airway constriction.

GNH India supplies Ipratropium Bromide/Salbutamol Neutec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing regulatory support for importers.

Manufacturer / TM Owner

Neutec Inhaler Ireland Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Ipratropium bromide/salbutamol is a bronchodilator used to manage airway obstruction in respiratory diseases.
  • Asthma: rapid relief of bronchospasm and improvement of airflow.
  • COPD: relief of bronchospasm and reduction of dyspnea.
  • Acute bronchospasm: prompt bronchodilation during sudden airway constriction episodes.

How It Works

  • Ipratropium bromide blocks muscarinic receptors on airway smooth muscle, preventing acetylcholine‑mediated bronchoconstriction, while salbutamol stimulates β2‑adrenergic receptors, increasing cyclic AMP and causing relaxation of airway smooth muscle. The combined actions produce additive bronchodilation and improve ventilation in obstructive airway diseases.

Side Effects

Common Side Effects

  • Dry mouth: reduced salivary secretion.
  • Throat irritation: local discomfort after inhalation.
  • Cough: transient irritation of the airway.
  • Tremor: mild muscle shaking, especially of the hands.
  • Headache: occasional mild headache.
  • Palpitations: sensation of rapid or irregular heartbeat.

Serious or Rare Side Effects

  • Paradoxical bronchospasm: worsening of airway constriction.
  • Tachycardia: significant increase in heart rate.
  • Arrhythmia: irregular heart rhythm.
  • Angioedema: swelling of face, lips, or throat.
  • Hypersensitivity reactions: rash, itching, or anaphylaxis.
  • Severe hypokalemia: low potassium levels, especially with high salbutamol doses.

Precautions & Warnings

Before using this inhalation product, consider the following precautions:

  • Assess cardiovascular status: monitor heart rate and blood pressure.
  • Evaluate for hypersensitivity: avoid if known allergy to either component.
  • Caution in patients with arrhythmias: salbutamol may exacerbate rhythm disorders.
  • Use with care in severe COPD: monitor for worsening respiratory status.
  • Avoid overdose: follow prescriber instructions closely.
  • Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Ipratropium bromide/salbutamol may interact with other medicines. Review the following:

Major Interactions (Avoid)

  • Non‑selective beta‑blockers: may reduce bronchodilator effect.
  • MAO inhibitors: increased risk of cardiovascular side effects.
  • Diuretics (e.g., furosemide): may potentiate hypokalemia with salbutamol.
  • Tricyclic antidepressants: heightened risk of tachycardia.
  • Other anticholinergic agents: additive dry‑mouth and urinary retention.

Moderate Interactions (Monitor Closely)

  • Theophylline: possible additive stimulant effect on the heart.
  • Sympathomimetic drugs: increased risk of tremor and palpitations.
  • ACE inhibitors: monitor for cough and bronchospasm.
  • Corticosteroids: may mask signs of infection.
  • Antihistamines: potential additive anticholinergic burden.

Frequently Asked Questions

Ipratropium Bromide/Salbutamol Neutec is a combination inhalation product used to provide rapid relief of bronchospasm in patients with asthma and chronic obstructive pulmonary disease (COPD). It works as a rescue medication to open narrowed airways during acute episodes.

Ipratropium bromide blocks muscarinic receptors on airway smooth muscle, preventing acetylcholine‑induced bronchoconstriction. This anticholinergic action reduces airway narrowing and complements the β2‑adrenergic effect of salbutamol.

The prescribed dose is determined by the treating physician based on the patient’s condition, severity of symptoms, and response to therapy. Dosage instructions are individualized and should be followed exactly as written on the prescription label.

Safety information for use in pregnancy or while breastfeeding is limited. Prescribers should weigh the potential benefits against any possible risks and consider alternative therapies if appropriate. Patients should discuss their specific situation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The combination of an anticholinergic (ipratropium) and a β2‑agonist (salbutamol) offers additive bronchodilation, often providing faster and more complete relief than either agent alone. This dual mechanism can be advantageous for patients with severe or refractory bronchospasm.

Store the inhaler at room temperature, below 25 °C, in its original packaging. Protect it from moisture, heat and direct sunlight. Keep the device upright and ensure the mouthpiece is clean before each use.

The product is administered by inhalation using a metered‑dose inhaler or nebulizer, as directed by the prescriber. Patients should inhale the prescribed number of puffs or nebulized doses, typically during an acute bronchospasm episode.

Serious risks include paradoxical bronchospasm, significant tachycardia or arrhythmia, severe hypersensitivity reactions such as angioedema, and marked hypokalemia, especially with high doses of salbutamol. Patients should seek immediate medical attention if these occur.

Individuals with known hypersensitivity to ipratropium, salbutamol, or any excipients in the formulation should avoid this product. Caution is also advised for patients with certain cardiac arrhythmias, severe hypertension, or those taking non‑selective beta‑blockers.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ipratropium Bromide, Salbutamol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT